What is the appropriate dosing of Kayexalate (sodium polystyrene sulfonate) for adults and children?

Kayexalate (Sodium Polystyrene Sulfonate) Dosing

For adults with hyperkalemia, administer 15 g orally one to four times daily (total daily dose 15-60 g) or 30-50 g rectally every 6 hours, but strongly consider newer potassium binders (patiromer or sodium zirconium cyclosilicate) instead due to SPS's serious gastrointestinal risks including fatal intestinal necrosis. 1

Adult Dosing

Oral Administration

• Standard dose: 15 g (four level teaspoons) administered 1-4 times daily 1
• Total daily dose range: 15-60 g 1
• Preparation: Suspend each dose in 3-4 mL of liquid per gram of resin (water or syrup); prepare fresh and use within 24 hours 1
• Timing: Administer at least 3 hours before or after other oral medications (6 hours in gastroparesis) 1
• Position: Patient must be upright during administration 1

Rectal Administration

• Dose: 30-50 g every 6 hours 1
• Preparation: Administer as warm emulsion in 100 mL aqueous vehicle, flush with 50-100 mL fluid 1
• Retention: Keep retained as long as possible, then follow with cleansing enema using non-sodium containing solution (up to 2 liters) 1

Dose-Response Evidence

Research demonstrates clear dose-dependent effects: 2

• 15 g oral: Reduces potassium by 0.39 mEq/L
• 30 g oral: Reduces potassium by 0.69 mEq/L
• 60 g oral: Reduces potassium by 0.91 mEq/L
• 30 g rectal: Reduces potassium by only 0.22 mEq/L (significantly less effective)

The 60 g oral dose achieved normokalemia in 50% more patients compared to 15 g (77% vs 23%) 2

Pediatric Dosing

For children with hyperkalemia, use 0.64 g/kg orally (mean effective dose from clinical data), though 1 g/kg rectally every 4 hours has been used 3, 4

• Oral route preferred: 91% of pediatric doses were given orally in clinical practice 3
• Rectal dosing: 1 g/kg every 4 hours until potassium normalizes 4
• Time to effect: Nadir potassium occurs at approximately 17 hours post-dose 3
• Limitation: May be insufficient as single-line therapy for severe hyperkalemia requiring >25% potassium reduction 3

Critical Safety Warnings

Life-Threatening Gastrointestinal Complications

Cases of fatal intestinal necrosis, ischemic colitis, perforation, and bleeding have been reported 5, 1, 6

• Mortality rate: 33% reported in patients experiencing serious GI adverse events 5
• Risk persists even with low-dose, short-duration therapy: Fatal outcomes reported after just 3 months of 30 g twice weekly 6
• SPS crystals can persist in intestinal mucosa for over 14 months after discontinuation 6

Contraindications 1

• Hypersensitivity to polystyrene sulfonate resins
• Obstructive bowel disease
• Neonates with reduced gut motility

High-Risk Populations to Avoid 1

• Patients without recent bowel movement post-surgery
• History of constipation, impaction, or inflammatory bowel disease
• Ischemic colitis or vascular intestinal atherosclerosis
• Previous bowel resection or obstruction
• Hypovolemia

DO NOT use concomitant sorbitol - this combination significantly increases intestinal necrosis risk 5, 1

Electrolyte Monitoring Requirements

Monitor potassium, calcium, and magnesium levels during therapy 1

• Hypokalemia risk: SPS is nonselective and can cause severe potassium depletion 5, 1
• Hypocalcemia and hypomagnesemia: Occur due to nonselective cation binding 5, 1
• Sodium load: Each 15 g dose contains 1500 mg sodium; monitor fluid-sensitive patients 5

Clinical Efficacy Limitations

Delayed and Variable Onset

• Onset of action: Several hours to days (variable) 5
• NOT appropriate for emergency treatment of life-threatening hyperkalemia 1
• Limited evidence base: Only one small 7-day randomized trial supports use 5

Modest Efficacy in Mild Hyperkalemia

In patients with mild hyperkalemia (5.0-5.9 mEq/L), SPS reduced potassium by only 0.14 mEq/L more than no treatment - a statistically significant but clinically marginal benefit 7

Preferred Alternative Agents

The 2021 Mayo Clinic guidelines recommend considering newer potassium binders (patiromer or sodium zirconium cyclosilicate) over SPS 5

Advantages of Newer Agents 5

• No fatal GI injuries reported (versus multiple fatal cases with SPS)
• Faster onset: SZC acts in 1 hour; patiromer in 7 hours (versus hours to days for SPS)
• Better tolerability: No sorbitol content
• Predictable efficacy: Robust clinical trial data

When SPS May Still Be Used

• Cost considerations limit access to newer agents
• Mild hyperkalemia in low-risk patients without GI contraindications
• Short-term use only (avoid chronic therapy given persistent tissue crystal deposition) 6

Special Populations

Hemodialysis Patients

SPS use in maintenance hemodialysis patients is controversial 8

• Sodium polystyrene sulfonate showed better potassium control than calcium polystyrene sulfonate 8
• Risk of sodium loading (serum sodium increased from 137.4 to 139.0 mEq/L) 8
• Only 4-5% of CKD/ESRD patients with hyperkalemia receive SPS prescriptions in real-world practice 9

Very Low Birth Weight Infants

Insulin/glucose infusion is superior to kayexalate enema in neonates 4

• Shorter duration of hyperkalemia with insulin therapy
• Lower incidence of intraventricular hemorrhage (15% vs 50%)
• Kayexalate contraindicated in neonates with reduced gut motility 1